The effects of azithromycin on patients with diffuse panbronchiolitis: a retrospective study of 29 cases.

J Thorac Dis

Department of Pulmonary Medicine, Affiliated Yixing People's Hospital, Jiangsu University, Yixing 214200, China.

Published: October 2013

Background: Diffuse panbronchiolitis (DPB), a chronic inflammatory disease of the airway, is treated with macrolide antibiotics. The ability of azithromycin to improve DPB prognosis, as detected by high-resolution computed tomography (HRCT) scans and lung function tests, has not been studied in a large retrospective of patients. Our study aims to investigate the effects of azithromycin on patients with DPB using lung function tests and radiologic images.

Methods: Twenty-nine patients with DPB were studied; their medical records were collected and analyzed retrospectively. Patients studied were hospitalized in the respiratory department of the Yixing Hospital, affiliated with Jiangsu University. Azithromycin was administered for 6-17 months. Changes in lung function and HRCT scans after treatment with azithromycin for six months were compared with pre-treatment values and images respectively.

Results: Azithromycin therapy for six months resulted in rapid improvements in lung function, demonstrated by forced expiratory volume in one second (FEV1.0%), forced expiratory volume in one second over the forced vital capacity (FEV1.0/FVC), and forced expiratory volume with 75% vital capacity (FEF75%) values. In addition, improvements were seen in small nodular shadows, dilated peripheral bronchi, bronchial wall thickening, and tree-in-bud pattern, as detected by chest HRCT scans.

Conclusions: Long-term therapy with azithromycin is effective for patients with DPB.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815720PMC
http://dx.doi.org/10.3978/j.issn.2072-1439.2013.09.01DOI Listing

Publication Analysis

Top Keywords

lung function
16
patients dpb
12
forced expiratory
12
expiratory volume
12
effects azithromycin
8
azithromycin patients
8
diffuse panbronchiolitis
8
hrct scans
8
function tests
8
volume second
8

Similar Publications

Acute lung injury (ALI) is a severe inflammatory condition of the respiratory system, associated with high morbidity and mortality. This study investigates the therapeutic potential of tocilizumab (TZ), an IL-6 receptor inhibitor, in mitigating lipopolysaccharide (LPS)-induced ALI by modulating the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway. An ALI model was established using LPS induction.

View Article and Find Full Text PDF

Background: Glucagon-like peptide-1 receptor agonists (GLP1RAs) are widely used in manageing type 2 diabetes mellitus and weight control. Their potential in treating ageing-related diseases has been gaining attention in recent years. However, the long-term effects of GLP1RAs on these diseases have yet to be fully revealed.

View Article and Find Full Text PDF

Background: Community mobility is a vital patient-centered outcome for older adults living in the community. These deficits in mobility are linked to social isolation, increased hospitalizations, and higher mortality rates. Impaired pulmonary function may be a modifiable risk factor for mobility decline, with existing inequities in lung health potentially contributing disproportionately to mobility loss among Black older adults.

View Article and Find Full Text PDF

Rationale: Preterm infants diagnosed with bronchopulmonary dysplasia (BPD) are thought to have fewer and larger alveoli than their term peers, but it is unclear to what degree this persists later in life.

Objectives: To investigate to what degree the distal airspaces are enlarged in adolescents born preterm and to evaluate the new Airspace Dimension Assessment (AiDA) method in investigating this group.

Methods: We investigated 41 adolescents between 15 and 17 years of age, of whom 25 were born very preterm (a gestational age <31 weeks, with a mean of 26 weeks) and 16 were term-born controls.

View Article and Find Full Text PDF

Chronic obstructive pulmonary disease (COPD) is among the most relevant comorbidity associated with lung cancer. The advent of innovative triple treatment approaches for COPD has significantly improved patients' quality of life and outcomes. Few data are available regarding the impact of triple inhaler therapy on patients featuring COPD and lung cancer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!